MeiraGTx Holdings plc

MeiraGTx Holdings Plc engages in the development of novel gene therapy treatments. It focuses on inherited retinal diseases, neurodegenerative diseases, and severe forms of xerostomia. It operates through the following geographical segments: United States, Ireland, Netherlands, and United Kingdom. Its pipeline includes AAV CNGB3, AAV-CNGA3, AAV-RPE65, AAV-RPGR, AAV-AQP1 and AAV-UPF1. The company was founded on March 20, 2015 and is headquartered in New York, NY.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

MeiraGTx Holdings Plc engages in the development of novel gene therapy treatments. The company was founded on March 20, 2015 and is headquartered in New York, NY.

LONDON and NEW YORK, April 19, 2022 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., President and Chief Executive Officer, will participate in the following investor and scientific conferences:

MeiraGTx to Participate in Upcoming Investor and Scientific Conferences

MeiraGTx Holdings PLC (MGTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

MeiraGTx Holdings PLC (MGTX) Stock Jumps 6.5%: Will It Continue to Soar?

MeiraGTx Holdings PLC (MGTX) delivered earnings and revenue surprises of 55.10% and 202.78%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

MeiraGTx Holdings PLC (MGTX) Reports Q4 Loss, Tops Revenue Estimates

- Phase 3 Lumeos Clinical Trial of botaretigene sparoparvovec (AAV-RPGR) for the Treatment of X-linked Retinitis Pigmentosa (XLRP) Enrolling and Dosing Patients - Received $30 Million Cash Milestone Payment from Janssen Pharmaceuticals, Inc. - Positive Preliminary Clinical Data from AQUAx AAV-hAQP1 Phase 1 Trial for Treatment of Grade 2/3 Radiation-Induced Xerostomia Announced - First In Vivo Data from Riboswitch Gene Regulation Platform at R&D Day Presented

MeiraGTx Reports Fourth Quarter and Full Year 2021 Financial and Operational Results

-MeiraGTx Receives $30 Million Cash Milestone Payment

MeiraGTx Receives Clinical Development Milestone Payment from Janssen

MeiraGTx says it has a triggering drug that can be used to turn implanted genes on and off in people. The technology could lessen the cost of treatment for many illnesses.

A Biotech Unveils Its New Gene Control Technology

LONDON and NEW YORK, Dec. 14, 2021 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ: MGTX), a vertically integrated, clinical stage gene therapy company, will host a virtual R&D Day via webcast and conference call on Wednesday, December 15, 2021, from 10:00 a.m. to 12:00 p.m. ET highlighting the Company's gene regulation platforms.

MeiraGTx to Host a Virtual Research and Development Day on Gene Regulation

MeiraGTx Holdings plc (NASDAQ: MGTX) has announced preliminary data from the ongoing Phase 1 AQUAx trial of AAV-hAQP1 for grade 2/3 radiation-induced xerostomia (RIX). Xerostomia, or Dry mouth, happens when a person cannot make enough saliva (spit).

MeiraGTx Reveals Interim Data From Phase 1 Trial Of Radiation-Induced Dry Mouth Symptom

LONDON and NEW YORK, Dec. 07, 2021 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced positive preliminary data from the ongoing Phase 1 AQUAx trial of AAV-hAQP1 for the treatment of grade 2/3 radiation-induced xerostomia (RIX).

MeiraGTx Announces Positive Preliminary Data from the AQUAx Phase 1 Clinical Trial of AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia

LONDON and NEW YORK, Nov. 29, 2021 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ: MGTX), a vertically integrated, clinical stage gene therapy company, today announced it will host a conference call and webcast to provide an update on the Company's AAV-hAQP1 Phase 1 AQUAx clinical trial for the treatment of radiation-induced xerostomia (RIX) on Tuesday, December 7, 2021, at 8:00 a.m. ET.

MeiraGTx to Provide a Xerostomia Clinical Program Update and Host a Virtual Research and Development Day on Gene Regulation

MeiraGTx Holdings PLC (MGTX) delivered earnings and revenue surprises of -13.46% and 38.94%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

MeiraGTx Holdings PLC (MGTX) Reports Q3 Loss, Tops Revenue Estimates

LONDON and NEW YORK, Nov. 10, 2021 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial results for the third quarter ended September 30, 2021 and provided an update on recent progress.

MeiraGTx Reports Third Quarter 2021 Financial and Operational Results

LONDON and NEW YORK, Nov. 09, 2021 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., President and Chief Executive Officer, will participate in the following virtual investor conferences:

MeiraGTx to Participate in Upcoming Virtual Investor Conferences

MeiraGTx Holdings PLC (MGTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: MeiraGTx Holdings PLC (MGTX) Q3 Earnings Expected to Decline

LONDON and NEW YORK, Sept. 28, 2021 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., president and chief executive officer, will present at the virtual Chardan 5th Annual Genetic Medicines Conference on Tuesday, October 5, 2021 at 10:30 a.m. ET.

MeiraGTx to Present at the Chardan 5th Annual Genetic Medicines Conference

uniQure

Solid Biosciences

Sarepta Therapeutics

Voyager Therapeutics

The promising gene therapy approach is being evaluated for varied diseases, such as hemophilia, Duchenne muscular dystrophy (DMD), Parkinson's disease, eye disease, and cancer among others

5 Gene Therapy Stocks Back in Focus on AbbVie/Regenxbio Deal

LONDON and NEW YORK, Sept. 09, 2021 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced new data from subjects treated in the Phase 1/2 dose escalation phase of Study MGT009 indicating AAV5-RPGR, an investigational gene therapy in development for the treatment of X-linked retinitis pigmentosa (XLRP), reverses course of disease progression when retinal function assessed 12 months following treatment with AAV5-RPGR is compared with retinal function in these same subjects up to 48 months prior to treatment. These data were presented today in an oral session at the EURETINA 2021 Virtual Meeting.

MeiraGTx Announces Data at EURETINA 2021 Virtual Meeting Demonstrating Reversal of Disease Progression Following Treatment with AAV5-RPGR in X-Linked Retinitis Pigmentosa

LONDON and NEW YORK, Aug. 11, 2021 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial results for the second quarter ended June 30, 2021 and provided an update on recent progress.

MeiraGTx Reports Second Quarter 2021 Financial and Operational Results

MeiraGTx Holdings PLC (MGTX) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

MeiraGTx Holdings PLC (MGTX) delivered earnings and revenue surprises of -25.58% and 83.80%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

MeiraGTx Holdings PLC (MGTX) Reports Q1 Loss, Tops Revenue Estimates

LONDON and NEW YORK, May 05, 2021 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., president and chief executive officer, will participate in multiple conferences in May.

MeiraGTx Announces Participation at Upcoming Investor Conferences

MeiraGTx Holdings (MGTX) has been struggling lately, but the selling pressure may be coming to an end soon

MeiraGTx (MGTX) Sees Hammer Chart Pattern: Time to Buy?

LONDON and NEW YORK, April 19, 2021 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., president and chief executive officer, and Stuart Naylor, Ph.D., chief development officer, will participate in a fireside chat at the Chardan Virtual Genetic Medicines Manufacturing Summit on Monday, April 26, 2021 at 1:45 p.m. ET.

MeiraGTx to Present at Chardan 5th Annual Genetic Medicines Manufacturing Summit

LONDON and NEW YORK, March 04, 2021 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., president and chief executive officer, will present at the Barclays Global Healthcare Conference on Thursday, March 11, 2021 at 11:30 a.m. ET.

News for MeiraGTx Holdings plc Stock (MGTX)